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assay was used to study the reassembly of tight junction 
proteins. Release of CXCL8, a typical marker for inflam-
mation, was quantified by ELISA.
Results In comparison with PGOS, FOS and inulin, VGOS 
showed the most pronounced protective effect on the DON-
induced impairment of the monolayer integrity, accelera-
tion of the tight junction reassembly and the subsequent 
CXCL8 release. DP2 and DP3 in concentrations occurring 
in VGOS prevented the DON-induced epithelial barrier dis-
ruption, which could be related to their high prevalence in 
VGOS. However, no effects of the separate DP GOS frac-
tions were observed on CXCL8 release.
Conclusions This comparative study demonstrates the 
direct, microbiota-independent effects of oligosaccharides 
on the intestinal barrier function and shows the differences 
between individual galacto- and fructo-oligosaccharides. 
This microbiota-independent effect of oligosaccharides 
depends on the oligosaccharide structure, DP length and 
concentration.
Keywords Caco-2 cells · CXCL8 · Degree of 
polymerization · Intestinal permeability · Non-digestible 
oligosaccharides · Tight junctions
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Purpose The direct effects of galacto-oligosaccharides 
(GOS), including Vivinal® GOS syrup (VGOS) and puri-
fied Vivinal® GOS (PGOS), on the epithelial integrity and 
corresponding interleukin-8 (IL-8/CXCL8) release were 
examined in a Caco-2 cell model for intestinal barrier dys-
function. To investigate structure–activity relationships, the 
effects of individual DP fractions of VGOS were evaluated. 
Moreover, the obtained results with GOS were compared 
with Caco-2 monolayers incubated with fructo-oligosac-
charides (FOS) and inulin.
Methods Caco-2 monolayers were pretreated (24 h) with 
or without specific oligosaccharides or DP fractions of 
VGOS (DP2 to DP6) before being exposed for 12 or 24 h 
to the fungal toxin deoxynivalenol (DON). Transepithelial 
electrical resistance and lucifer yellow permeability were 
measured to investigate barrier integrity. A calcium switch 
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GOS  Galacto-oligosaccharides
HMOs  Human milk oligosaccharides
HPAEC-PAD  High-performance anion-exchange chro-
matography with pulsed amperometric 
detection
IEC  Intestinal epithelial cells
IL8/CXCL8  Interleukin-8
Lac  Lactose
lcFOS  Long-chain FOS or inulin
LY  Lucifer yellow
PBMCs  Peripheral blood mononuclear cells
PGOS  Purified Vivinal® GOS
TEER  Transepithelial electrical resistance
VGOS  Vivinal® GOS syrup
Wt %  Weight percent
Introduction
Human milk oligosaccharides (HMOs) play an essential 
role in the postnatal growth and development of the intesti-
nal and immune system [1]. As the sufficient supply of the 
neonate with HMOs cannot always be guaranteed, various 
attempts were made to design alternative prebiotic oligo-
saccharides that mimic the gut health-promoting effects of 
HMOs. At present, prebiotic oligosaccharides, for example 
the mixture of 90 % GOS/10 % lcFOS, aiming to mimic 
molecular size distribution of neutral HMOs, are widely 
used in infant formulas [2, 3]. Although these neutral oli-
gosaccharides are structurally different from HMOs, they 
have prebiotic activities, and clinical investigations have 
confirmed that infants given such a formula containing 
GOS or GOS/lcFOS achieve an intestinal microbiota com-
position comparable to that of breastfed infants [4, 5]. 
Besides the effects of GOS and the mixture of GOS/lcFOS 
on the gut microbiota [6, 7], direct interactions of these oli-
gosaccharides with intestinal epithelial cells have recently 
been described by our group and others [8–11]. It has been 
shown that these oligosaccharides improve and protect 
the intestinal barrier integrity and modulate the immune 
responses of epithelial cells.
GOS and FOS differ in origin and structure, and it has 
been suggested previously that the biological function of 
oligosaccharides is influenced by their structures, molecu-
lar weight and type of glycosidic linkages [12, 13]. GOS 
are oligosaccharides based on the milk sugar lactose, and 
the oligomers [degree of polymerization (DP)2–8] are 
produced by glycosylation of lactose using the enzyme 
β-galactosidase [14]. Inulin, also called long-chain FOS 
(lcFOS), corresponds to unprocessed chicory inulin, mainly 
composed of fructans (DP2-60) ending with a terminal 
glucose monomer, whereas FOS are composed of partially 
hydrolyzed inulin (DP2-8), and more molecules end with 
a fructose rather than with a glucose monomer [15, 16]. In 
addition to origin and structure, the specific DP composi-
tion is believed to influence the prebiotic activity and the 
degree of fermentation of oligosaccharides, since distinct 
sensitivity of human gut bacteria to selected DP of oligo-
saccharides has been observed [13, 17, 18]. However, the 
direct interactions of individual DP fractions with intestinal 
epithelial cells have not yet been investigated.
In the current study, we aimed to compare direct, micro-
biota-independent effects of different galacto-oligosaccha-
rides, on dysregulated intestinal epithelial barrier function 
and the related inflammatory response. Monolayers of the 
human intestinal epithelial cell line, Caco-2, served as 
a model system for intestinal barrier function, while the 
fungal toxin deoxynivalenol (DON) was used as a model 
compound to impair the intestinal integrity as previously 
described by Akbari et al. [19]. Considering the protective 
effects of GOS in this Caco-2 cell model, we compared 
these results to the effects of FOS and inulin and further 
evaluated the effect of individual DP fractions of GOS 
(ranging from DP2 to DP6).
Materials and methods
Deoxynivalenol (DON)
Purified DON (D0156; Sigma-Aldrich, St Luis, MO, USA) 
was dissolved in pure ethanol (99.9 %, JT Baker, Deven-
ter, The Netherlands) and stored at −20 °C. The mycotoxin 
DON was selected as model compound to impair intesti-
nal barrier integrity in the cell culture experiments. DON 
was diluted to a concentration of 4.2 μM in complete cell 
culture medium and added to the apical side as well as to 
the basolateral side of the transwell inserts for either 12 or 
24 h. This DON concentration was selected on the basis of 
our previous results and did not affect the viability of the 
Caco-2 cells [19].
Oligosaccharides
Galacto-oligosaccharides (Vivinal® GOS syrup (VGOS, 
59 % GOS on dry matter) and purified Vivinal® GOS 
(PGOS, 97 % GOS on dry matter) without the monomeric 
sugars glucose, galactose and lactose were provided by 
FrieslandCampina Domo (Borculo, The Netherlands). 
Fructo-oligosaccharides (FOS, Orafti®P95) and inulin 
(Orafti®LGI) were obtained from Beneo Orafti (Tienen, 
Belgium). The detailed composition of the applied oligo-
saccharides is summarized in Online Resource 1 (related 
to Figs. 1, 2, 3, 4, 7, 8) and Online Resource 2 (related to 
Fig. 5, 6), and the oligosaccharide structures are schemati-
cally depicted in Online Resource 3. The concentrations 
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used in this study are calculated based on the pure oligo-
saccharide fractions.
Purification of GOS
Purified GOS with <3 % (w/w dry matter) monomers and 
lactose (purified from the lactose-based prebiotic Vivinal® 
GOS syrup) were used. For the purification, Vivinal® GOS 
syrup was enzymatically treated with a lactase to hydro-
lyze the lactose into glucose and galactose, after which the 
monosaccharides were removed by nanofiltration on labo-
ratory scale [18]. By the purification process of Vivinal® 
GOS syrup, next to lactose, also a part of the DP2 GOS is 
removed (Fig. 1).
High‑performance anion‑exchange chromatography 
with pulsed amperometric detection (HPAEC‑PAD)
Specific chain length profiles were characterized by 
HPAEC using a Dionex ICS 3000 system (Dionex, Sunny-
vale, CA, USA), equipped with a Dionex CarboPac PA-1 
column (2 × 250 mm) in combination with a CarboPac 
PA-1 guard column (2 × 50 mm) and a ISC5000 ED detec-
tor (Dionex) in the PAD mode as previously described [20, 
21]. The individual peaks were characterized by compar-
ing the obtained HPAEC-PAD profiles with SEC GOS-DP 
fractions and mass spectrometry.
Size exclusion chromatography (SEC)
The oligosaccharides present in Vivinal® GOS syrup were 
separated by SEC. Vivinal® GOS syrup was fractionated 
using a XK50 column (length 60 cm, GE Healthcare, Pitts-
burgh, PA, USA) filled with Bio-Gel P-2 Gel Resin (Fine 
45–90 μm, BioRad Laboratories, Hercules, CA, USA) con-
nected to a AktaPrime Plus (GE Healthcare, Pittsburgh, 
PA, USA). The jacket of the column was connected to a 
water bath in order to maintain the temperature at 50 °C. 
Fig. 1  VGOS and PGOS characteristics. HPAEC-PAD elution pat-
terns of Vivinal® GOS syrup and purified GOS. Numbers 2–6 corre-
spond to galacto-oligosaccharides having a degree of polymerization 
from 2 to 6. G and L represent galactose/glucose and lactose, respec-
tively
Fig. 2  Different effects of VGOS and PGOS on the DON-induced 
impairment of the Caco-2 cell monolayer integrity. Caco-2 cells were 
pretreated apically and basolaterally with increasing concentrations 
(0.5, 1 and 2 %) of VGOS or PGOS (24 h) prior to the addition of 
DON (4.2 μM) (apical and basolateral compartments) for another 
24 h. Subsequently, the TEER (a) and the translocation of lucifer yel-
low from the apical to the basolateral compartment (b) were meas-
ured. Results are expressed as a percentage of initial value (TEER) 
or the amount of tracer transported [ng/(cm2 × h)] as mean ± SEM 
of three independent experiments, each performed in triplicate 
(***P < 0.001: significantly different from the unstimulated cells; 
^P < 0.05, ^^^P < 0.001: significantly different from the DON-stim-
ulated cells; #P < 0.05, ###P < 0.001: significantly different from each 
other)
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Diluted Vivinal® GOS syrup (approximately 30 % on DM) 
was injected onto the column (flowrate: 1.0 ml/min) using 
a 2-ml sample loop and eluted with demineralized water. 
Sampling was based on refractive index, and samples cor-
responding to the same DP were pooled and subsequently 
freeze-dried.
The Caco‑2 cell model
Human epithelial colorectal adenocarcinoma (Caco-2) cells 
obtained from American Type Tissue Collection (Code 
HTB-37) (Manassas, VA, USA, passages 90–102) were 
used according to established methods, also described 
by Akbari et al. [19]. In brief, cells were cultured in Dul-
becco’s modified Eagle medium (DMEM) and seeded at a 
density of 0.3 × 105 cells into 0.3 cm2 high pore density 
(0.4 μm) inserts with a polyethylene terephthalate mem-
brane (BD Biosciences, Franklin Lakes, NJ, USA) placed 
in a 24-well plate. The Caco-2 cells were maintained in a 
humidified atmosphere of 95 % air and 5 % CO2 at 37 °C. 
Fig. 3  VGOS time-dependently accelerated tight junction reassem-
bly after calcium deprivation in Caco-2 cells. Caco-2 cells were pre-
treated apically and basolaterally with increasing concentrations (0.5, 
1 and 2 %) of VGOS (a) or PGOS (b) (24 h) prior to transient cal-
cium deprivation with HBSS-EGTA to disrupt tight junction proteins. 
TEER was measured at the indicated time points (0, 2, 4, 6, 12 and 
24 h) during recovery in complete, calcium-containing DMEM with 
either VGOS (a) or PGOS (b). Results are expressed as a percentage 
of initial value as mean ± SEM of three independent experiments, 
each performed in triplicate (*P < 0.05, **P < 0.01, ***P < 0.001: 
significantly different from the untreated cells)
Fig. 4  VGOS was able to suppress the DON-induced increase in 
CXCL8 release by Caco-2 cells. Caco-2 cells were pretreated apically 
and basolaterally with increasing concentrations (0.5, 1 and 2 %) of 
VGOS or PGOS (24 h) prior to the addition of DON (4.2 μM) (api-
cal and basolateral compartments) for 24 h. CXCL8 secretion into 
medium of apical (a) and basolateral (b) compartments was measured 
by ELISA. Results are expressed as pg/ml as mean ± SEM of three 
independent experiments, each performed in triplicate (***P < 0.001; 
significantly different from the unstimulated cells. ^P < 0.05, 
^^P < 0.01, ^^^P < 0.001: significantly different from the DON-stim-
ulated cells; #P < 0.05, ##P < 0.01: significantly different from each 
other)
Fig. 5  Combined DP fractions of VGOS mimicked VGOS in pre-
venting DON-induced barrier disruption and CXCL8 release, 
whereas only individual DP2 and DP3 can prevent DON-induced bar-
rier disruption. Caco-2 cells were pretreated apically and basolater-
ally with VGOS, individual DP fractions of GOS (ranging from DP2 
to DP6) and combination of different DP fractions (DP2–DP6) with 
or without supplementation with glucose (Glc) and galactose (Gal) 
(24 h) prior to the addition of DON (4.2 μM) (apical and basolateral 
compartments) for 12 h. Subsequently, TEER (a, b), the transport 
of lucifer yellow (c, d) and CXCL8 release into the apical (e, f) and 
basolateral (g, h) compartment were measured. Results are expressed 
as a percentage of initial value (TEER), the amount of tracer trans-
ported [ng/(cm2 × h)] or pg/ml CXCL8 as mean ± SEM of three 
independent experiments, each performed in triplicate (**P < 0.01, 
***P < 0.001: significantly different from the unstimulated cells; 
^P < 0.05, ^^P < 0.01, ^^^P < 0.001: significantly different from the 
DON-stimulated cells; #P < 0.05, ##P < 0.01: significantly different 
from each other)
▸
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After 17–19 days of culturing, a confluent monolayer was 
obtained with a mean TEER exceeding 400 Ω cm2 meas-
ured by a Millicell-Electrical Resistance System voltohm-
meter (Millipore, Temecula, CA, USA).
Different concentrations (0.5, 1 and 2 %) of the oligo-
saccharides VGOS (v/v), PGOS (w/v), FOS (w/v) and 
inulin (w/v) and different DP fractions of VGOS [either in 
equimolar concentrations as present in VGOS or in a con-
centration of 0.75 % (w/v)] were prepared by dissolving 
in complete cell culture DMEM. Subsequently, the cells 
were preincubated with the different oligosaccharides or 
DP fractions of VGOS from apical side as well as basolat-
eral side of the transwell inserts for 24 h before being chal-
lenged with DON in the presence of the different oligosac-
charides or DP fractions of VGOS for another 24 or 12 h, 
respectively. Prior to the functional assays described below, 
the potential cytotoxicity of the different oligosaccharides 
or DP fractions of VGOS in Caco-2 cells had been evalu-
ated by measuring lactate dehydrogenase (LDH) leakage 
(Promega Corp., Madison, WI, USA). These control exper-
iments confirmed that none of the above oligosaccharides 
induced any cytotoxicity in Caco-2 cells at the concentra-
tions used in the assays (data not shown).
Transepithelial electrical resistance (TEER) 
measurement
The integrity of the Caco-2 cell monolayer grown on 
inserts was investigated by monitoring the TEER across 
the monolayer. A Millicell-ERS voltohmmeter connected 
to a pair of chopstick electrodes was used to measure the 
TEER values either 12 or 24 h after DON stimulation with 
Fig. 6  Different effects on the Caco-2 cell monolayer induced by 
individual DP fractions of VGOS with equal concentrations. Caco-2 
cells were pretreated apically and basolaterally with VGOS (0.75 
and 2 %) or individual DP fractions of VGOS (0.75 %, ranging from 
DP2 to DP5) (24 h) prior to the addition of DON (4.2 μM) (apical 
and basolateral compartments) for 12 h. Subsequently, TEER (a), the 
transport of lucifer yellow (b) and CXCL8 secretion into medium of 
apical (c) and basolateral (d) compartments were measured. Results 
are expressed as a percentage of initial value (TEER), the amount of 
tracer transported [ng/(cm2 × h)] or pg/ml CXCL8 as mean ± SEM 
and are representative of two independent experiments, each per-
formed in triplicate (***P < 0.001: significantly different from the 
unstimulated cells; ^P < 0.05, ^^P < 0.01, ^^^P < 0.001: signifi-
cantly different from the DON-stimulated cells; #P < 0.05, ##P < 0.01, 
###P < 0.001: significantly different from each other)
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or without pretreatment with the different oligosaccharides 
or DP fractions of VGOS for 24 h. Results are expressed as 
a percentage of the initial value.
Paracellular tracer flux assay
Transport studies from the apical side to the basolateral 
side of a Caco-2 cell monolayer were performed using a 
membrane-impermeable molecule, lucifer yellow (LY, 
molecular mass: 0.457 kDa, Sigma, St. Luis, MO, USA). 
LY was added at a concentration of 16 μg/ml to the apical 
compartment (350 μl) in the transwell plate for 4 h, and the 
paracellular flux was determined by measuring the fluores-
cence intensity in the basolateral compartment with a spec-
trophotofluorimeter (FLUOstar Optima, BMG Labtech, 
Offenburg, Germany) set at excitation and emission wave-
lengths of 410 and 520 nm, respectively.
Calcium switch assay
Caco-2 cells grown on inserts were pretreated with various 
concentrations (0.5, 1 and 2 %) of different oligosaccha-
rides (VGOS, PGOS, FOS and inulin) on both sides of the 
transwell inserts for 24 h. Subsequently, Caco-2 cells were 
exposed transiently for 20 min to 2 mM ethylene glycol-
bis(2-aminoethyl ether)N,N,N′,N′-tetraacetic acid (EGTA) 
(Sigma, St. Luis, MO, USA) in calcium- and magnesium-
free Hanks’ balanced salt solution (HBSS) (Gibco, Invitro-
gen, Carlsbad, CA, USA) to disrupt tight junction proteins 
as previously described [8]. At the end of the incubation 
period, the cells were rinsed and allowed to recover either in 
complete cell culture DMEM (containing 2 mM CaCl2) or 
in DMEM supplemented with the addition of various con-
centrations (0.5, 1 and 2 %) of the different oligosaccharides. 
During this recovery period, reassembly of tight junctions 
and restoration of barrier function were determined by meas-
uring the TEER at various time points (2, 4, 6, 12 and 24 h). 
The results are expressed as a percentage of initial value.
CXCL8 secretion
The inflammatory marker, CXCL8, was quantified in the 
medium of the apical side and the basolateral side of the 
Caco-2 transwell inserts in response to the treatments. 
CXCL8 concentrations were measured by using the human 
IL-8 ELISA (BD Biosciences, Pharmingen, San Diego, 
CA, USA) according to manufacturer’s instructions.
Statistical analysis
Experimental results are expressed as mean ± SEM. 
Analyses were performed by using GraphPad Prism (ver-
sion 6.05) (GraphPad, La Jolla, CA, USA). Differences 
between groups were statistically determined by using one-
way ANOVA, with Bonferroni’s post hoc test. Results were 
considered statistically significant when P < 0.05.
Results
VGOS and PGOS characteristics
The HPAEC-PAD chromatograms of VGOS and PGOS 
(Fig. 1) clearly demonstrated that both GOS samples are 
complex mixtures of oligosaccharides with a DP of mainly 
2–6 and various isomers per DP (Online Resource 3). 
PGOS, derived from VGOS, was predominantly lacking 
the monosaccharides and lactose, although also some other 
components of GOS-DP2 were (partly) removed.
Different effects of VGOS and PGOS on the 
DON‑induced impairment of the Caco‑2 cell monolayer 
integrity
Pretreatment with VGOS prevented the DON-induced 
decrease in TEER values in a concentration-dependent man-
ner as depicted in Fig. 2a, while only the highest concen-
tration of PGOS significantly attenuated the DON-induced 
TEER decrease; however, this effect was significantly lower 
compared with 2 % VGOS (Fig. 2a). In line with the effects 
on the observed TEER values, the DON-induced increase 
in tracer transport (LY) was significantly decreased by 1 % 
VGOS, 2 % VGOS and 2 % PGOS (Fig. 2b).
Fig. 7  FOS and inulin characteristics. HPAEC-PAD elution patterns 
of FOS (a) and inulin (b). The Fn series represent oligomers consist-
ing of fructose only, whereas the GFn series represent fructose oli-
gomers terminated with a terminal glucose molecule. The number of 
fructose units within an oligomer is indicated by n
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VGOS time‑dependently accelerates tight junction 
reassembly after calcium deprivation in Caco‑2 cells
It was demonstrated that 2 % VGOS caused a time-
dependent acceleration in tight junction reassembly over 
a period of 24 h (Fig. 3a), and the first significant effect 
on TEER restoration was already observed 4 h after 
calcium recovery. In addition, 1 % VGOS also showed 
a significant improvement in TEER values after 24-h 
recovery. Caco-2 cells incubated with 2 % PGOS showed 
only improved restoration in TEER after 24-h recovery, 
whereas the other tested PGOS concentrations (0.5 and 
1 %) did not accelerate the tight junction reassembly 
(Fig. 3b).
Fig. 8  Different effects of FOS and inulin on the DON-induced bar-
rier disruption, tight junction reassembly and CXCL8 release. Caco-2 
cells were pretreated apically and basolaterally with increasing con-
centrations (0.5, 1 and 2 %) of FOS or inulin (24 h) prior to the addi-
tion of DON (4.2 μM) (apical and basolateral compartments) for 
another 24 h (a, b, e, f) or transient calcium deprivation with HBSS-
EGTA to disrupt tight junction proteins (c, d). Subsequently, TEER 
values at the indicated time points (a, c, d), the transport of lucifer 
yellow (b) and CXCL8 secretion into medium of apical (e) and baso-
lateral (f) compartments were measured. Results are expressed as a 
percentage of initial value (TEER), the amount of tracer transported 
[ng/(cm2 × h)] or pg/ml CXCL8 as mean ± SEM of three independ-
ent experiments, each performed in triplicate (*P < 0.05, **P < 0.01, 
***P < 0.001: significantly different from the unstimulated cells; 
^P < 0.05, ^^P < 0.01: significantly different from the DON-stimu-
lated cells; #P < 0.05: significantly different from each other)
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VGOS and not PGOS is able to suppress the 
DON‑induced increase in CXCL8 release by Caco‑2 
cells
The DON-induced increased levels of secreted CXCL8 
could be only prevented by preincubation with 1 and 2 % 
VGOS as observed by a concentration-dependent decrease 
in CXCL8 release on both sides (Fig. 4a, b). PGOS expo-
sure to Caco-2 cells did not affect CXCL8 secretion into 
neither the apical nor the basolateral compartment of the 
transwell system (Fig. 4a, b).
Supplementation of glucose, galactose and lactose 
to PGOS does not mimic the effect of VGOS 
against DON‑induced barrier disruption and CXCL8 
release
Supplementation of glucose, galactose and lactose (in 
equimolar concentrations as present in 2 % VGOS, Online 
Resource 2) to 2 % PGOS did not improve the effect of 
PGOS on the DON-induced gut barrier impairment as 
observed by TEER and paracellular flux of LY (Online 
Resource 4). In addition, this supplementation to PGOS did 
not mimic the protective effect of VGOS against the DON-
induced increase in CXCL8 release (Online Resource 4).
Combined DP fractions of VGOS mimic VGOS 
in preventing DON‑induced barrier disruption 
and CXCL8 release, whereas only individual DP2 
and DP3 prevent the DON‑induced barrier disruption
Pretreatment with DP2 or DP3 (in equimolar concentra-
tions as present in VGOS) prevented the DON-induced 
decrease in TEER values (Fig. 5a). The DON-induced 
increase in tracer transport was significantly decreased by 
DP2, whereas the effect of DP3 was not significantly dif-
ferent (P = 0.076) (Fig. 5c). None of the individual DP4, 
DP5 or DP6 induced a preventive effect on the DON-
induced intestinal epithelial barrier impairment as observed 
by TEER (Fig. 5a) and paracellular flux of LY (Fig. 5c), 
and none of the individual DP fractions (ranging from DP2 
to DP6) was able to prevent the DON-induced increase in 
secreted CXCL8 (Fig. 5e, g). The combination of different 
DP fractions of GOS (ranging from DP2 to DP6 in equimo-
lar concentrations as present in VGOS) with or without glu-
cose and galactose supplementation did show a protective 
effect against DON-induced gut barrier impairment and 
CXCL8 release comparable to the effect of VGOS (Fig. 5b, 
d, f, h). In addition, the effects of individual DP fractions 
and the combined DP fractions were also determined in 
non-treated Caco-2 cells. These results indicated that nei-
ther individual DP fractions nor the combination of dif-
ferent DP fractions with or without glucose and galactose 
supplementation affects gut barrier function and CXCL8 
release (Online Resource 5).
Different effects on the Caco‑2 cell monolayer induced 
by individual DP fractions of VGOS with equal 
concentrations
Next to investigating the effect of DPs in equimolar con-
centrations as present in VGOS, we studied the effects 
of the individual DP fractions in equal concentrations of 
0.75 % to clarify concentration-dependent effects of DP 
fractions. Pretreatment with 0.75 % of individual DP2, 
DP3 or DP5 significantly prevented the DON-induced 
decrease in TEER values and DON-induced increase in 
tracer transport (Fig. 6a, b), and this effect was similar to 
that of 0.75 % VGOS (Fig. 6a, b). DP4 (0.75 %) did not 
significantly affect the DON-induced gut barrier impair-
ment as measured by TEER (Fig. 6a) and paracellular flux 
of LY (Fig. 6b). In addition, neither 0.75 % VGOS nor the 
individual DP fractions (0.75 %, ranging from DP2 to DP5) 
attenuated the DON-induced increase in CXCL8 release 
(Fig. 6c, d).
FOS and inulin characteristics
Figure 7 shows the HPAEC-PAD chromatograms of FOS 
(a) and inulin (b) and demonstrates that FOS clearly 
contain oligosaccharides up to DP7–8, built up by fruc-
tose residues (Fn series) and by fructose residues with 
a terminally linked glucose moiety (GFn series). Inulin 
mainly consists of fructose chains terminated with a glu-
cose molecule representing a wide range of DPs (Online 
Resource 3).
Different effects of FOS and inulin on the DON‑induced 
barrier disruption, tight junction reassembly 
and CXCL8 release
Furthermore, the microbiota-independent effects of GOS 
were compared to oligosaccharides with a different struc-
ture and DP, including inulin and FOS. The highest con-
centration of FOS (2 %) significantly modulated the DON-
induced epithelial barrier disruption as measured by TEER 
values and paracellular flux of LY, whereas none of the 
tested inulin concentrations induced a preventive effect on 
the barrier integrity of the Caco-2 monolayer (Fig. 8a, b). 
Caco-2 cells incubated with 2 % FOS or 2 % inulin showed 
both improved restoration in TEER 24 h after calcium 
recovery, whereas the other tested concentrations (0.5 and 
1 %) did not accelerate the tight junction reassembly after 
calcium deprivation (Fig. 8c, d). DON-induced increase in 
CXCL8 secretion was affected by neither FOS nor inulin 
(Fig. 8e, f).
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Discussion
Non-digestible oligosaccharides, including GOS and mix-
tures of GOS/lcFOS, are commonly used in infant formula 
as an alternative for human milk oligosaccharides, which are 
not commercially available [12, 22]. Gut health-promoting 
effects of GOS and GOS/lcFOS are not limited to the mod-
ulation of the intestinal microbiota, since also direct inter-
action between intestinal epithelial cells (IEC) and these 
oligosaccharides has recently been described [8–11]. The 
prebiotic activity of GOS and FOS is believed to be deter-
mined by their unique structure and specific DP composi-
tion [12, 13, 17, 18]. However, the effect of structure and 
DP composition of GOS or FOS on direct interaction with 
IEC has never been studied. Hence, in the current study the 
direct effects of Vivinal® GOS syrup, purified Vivinal® GOS 
and their DP fractions were compared in a DON-stimulated 
Caco-2 cell model for intestinal barrier dysfunction as pre-
viously described [19]. We aimed to understand which DP 
fractions of VGOS are responsible for the observed protec-
tive effects. Furthermore, the effects of oligosaccharides 
with a different structure and DP than GOS, such as inulin 
and FOS, were examined in this Caco-2 cell model.
The mycotoxin DON was used as a model compound 
to impair the intestinal integrity. DON is a 12,13-epoxy-
trichothecene and is known to directly impair tight junc-
tion integrity and to induce an inflammatory response [19, 
23, 24]. Our group recently found that GOS stimulate the 
tight junction reassembly and in turn mitigate the deleteri-
ous effects of DON on the intestinal barrier of Caco-2 cells 
and this effect is not related to a direct interaction between 
DON and GOS [8].
GOS are derived from lactose and consist of a chain of 
galactose units with a terminal glucose monomer, different 
glycosidic linkages (e.g., β(1–4) and β(1–6)), and the DP 
varies between 2 and 8 [14, 25]. GOS structures have the 
lactose building block in common with HMOs, although 
the latter is more complex, since HMO oligomers may also 
have galactose and N-acetylglucosamine (GlcNAc) in their 
backbone, which are further substituted with fructose and 
neuraminic acid [2, 26]. Holscher et al. [27] reported differ-
ent roles for specific HMOs in the differentiation and bar-
rier function of Caco-2 cells.
In the current study, VGOS was most effective and 
purified GOS (PGOS) was significantly less effective 
with respect to the improvement of the impairment of the 
Caco-2 cell monolayer integrity as well as the modula-
tion of immune responses, including CXCL8 release. The 
monosaccharides (glucose and galactose) and disaccharide 
(lactose) present in Vivinal® GOS syrup were not respon-
sible for this superior effect of VGOS over PGOS, since 
combined supplementation of glucose, galactose and lac-
tose to PGOS did not mimic the effect of VGOS against 
the DON-induced effects, as shown by the current experi-
ments. We previously confirmed that similar concentrations 
of these saccharides present in the 2 % GOS solution did 
not affect the DON-induced impairment of Caco-2 mon-
olayer integrity [8]. Comparing the HPAEC elution patterns 
(Fig. 1), another difference between VGOS and PGOS is 
the amount of DP2, which is partly lost during the purifica-
tion process. It could therefore be hypothesized that DP2 is 
driving the higher potency of VGOS. In our experiments, 
we demonstrated that isolated DP2 and DP3 fractions (in 
equimolar concentrations as present in VGOS) significantly 
prevented the DON-induced barrier disruption, whereas no 
effect of the larger DPs (equal or above DP4) was observed. 
The prominent effect of DP2 and DP3 seems to be related 
to their high prevalence in the VGOS mixture. When we 
tested equal concentrations (0.75 %) of all available DPs, 
only DP4 was not effective in preventing the Caco-2 mon-
olayer disruption by DON.
Related to our results, the DP concentration and to a 
lesser extent the DP length may be crucial for the observed 
protective effects of galacto-oligosaccharides. Previous 
studies had already indicated that the effect of individual 
oligosaccharides on the intestinal microbiota can be related 
to their DP composition. Ladirat et al. [18] described that 
the addition of GOS or a DP3 fraction to a human fecal 
inoculum resulted in the highest Bifidobacterium spp. 
increase, whereas the DP4 and DP5 fractions displayed the 
lowest increase. In line with our results, they did not find 
significant differences between the DP GOS fractions and 
VGOS at similar concentrations. In a study with maltose-
based oligosaccharides, DP3 oligomers showed the high-
est selectivity toward bifidobacteria, and oligosaccharides 
above DP7 did not promote the growth of beneficial bac-
teria, including bifidobacteria [13]. In contrast, the pres-
ence of the larger DP fractions within GOS was effective 
in restoring the microbiota following an antibiotic-induced 
dysbacteriosis [18], whereas Sinclair et al. [28] showed 
that in particular higher DP GOS fractions were capable of 
inhibiting the in vitro binding of Vibrio cholerae toxin to its 
GM1 receptor. We therefore speculate that DP length of oli-
gosaccharides is related to different physiological effects.
In contrast to galacto-oligosaccharides, inulin (or 
lcFOS) consists of a mixture of fructose residues linked by 
β(2–1) fructosyl-fructose glycosidic bonds with a glucose 
monomer at the end of almost each fructose chain within 
a DP range of 2–60. FOS have been produced from inu-
lin by partial enzymatic hydrolysis and differ from inulin 
to its degree of polymerization (DP2-8), and fructose oli-
gomers occur with or without the presence of a terminal 
glucose moiety (Fig. 7) [16, 20]. Schematic structures of 
GOS, FOS and inulin are depicted in Online Resource 3. 
Only 2 % FOS showed moderate, but significant, protective 
effects against intestinal barrier dysfunction as observed 
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by TEER recovery and decreased LY paracellular flux, 
whereas none of the mentioned parameters were affected 
by inulin. Since the DP of both GOS and FOS varies from 
2 to 8, we can speculate that these smaller DP fractions 
(DP2–8) are important for inducing the protective effects 
on barrier integrity compared with higher DP fractions 
DP9-60. Also in a different experimental setting, Shoaf 
et al. [29] described that GOS were most effective in pre-
venting bacterial colonization and pathogen invasion by 
their anti-adhesive capacity compared with the other oligo-
saccharides, including FOS, inulin, lactulose and raffinose.
With regard to the potential anti-inflammatory proper-
ties of oligosaccharides, our results demonstrate that only 
VGOS was able to prevent the DON-induced CXCL8 
release, whereas PGOS, the separate GOS-DP fractions, 
FOS and inulin did not prevent CXCL8 secretion. The 
anti-inflammatory activity of VGOS was also observed 
by Vendrig et al. [30] since peripheral blood mononuclear 
cells (PBMCs) derived from VGOS-treated foals were 
less responsive to a lipopolysaccharide challenge and did 
show lower IFN-γ and IL-6 mRNA expression levels. Dif-
ferences in chain length between different FOS-products 
could be responsible for differential effects in skewing the 
cytokine balance, since Vogt et al. [20] found a positive 
correlation between chain length of FOS and IL-10/IL-12 
ratios in human PBMCs. Different in vitro and ex vivo 
studies displayed that short-chain FOS and long-chain FOS 
are able to induce a more anti-inflammatory or pro-inflam-
matory condition, respectively [20, 31, 32]. In addition, 
higher concentrations of inulin or short-chain FOS (10 %) 
did significantly decrease the CXCL8 gene expression 
induced by Citrobacter rodentium [33], and in unstimulated 
Caco-2 cells, FOS reduced the CXCL8, IL-12 and TNF-α 
gene expression via activation of peptidoglycan recognition 
protein 3 (PGlyRP3) and peroxisome proliferator-activated 
receptor γ (PPARγ) [11]. In the presence of a GOS/lcFOS 
mixture, a potential role for Toll-like receptor (TLR)-9 and 
galectin-9 in modulating cytokine production has been 
demonstrated [34, 35]. In contrast, Ortega-González et al. 
[36] hypothesized that GOS and FOS are TLR4 ligands in 
intestinal epithelial cells, which may be a relevant mech-
anism for the immunomodulatory effects of prebiotics. 
However, this latter mechanism cannot explain our results 
in the Caco-2 cell model, since these cells do not express 
TLR4 [37]. The direct effect of VGOS on cytokine expres-
sion and release is possibly mediated by other pattern rec-
ognition receptor(s), and this signaling pathway seems to 
be galacto-oligosaccharide-specific.
In summary, this study for the first time compared 
direct, microbiota-independent effects, of defined oligo-
saccharides, including GOS (Vivinal® GOS syrup (VGOS) 
and purified Vivinal® GOS (PGOS)), and their related DPs, 
as well the plant-derived oligosaccharides FOS and inulin 
on intestinal epithelial cells. It can be concluded that the 
tested oligosaccharides have different capacities to regulate 
the DON-disrupted epithelial monolayer and the related 
immune response. VGOS showed the most significant pro-
tective effect on all tested parameters in a concentration-
dependent manner. Overall, differences in oligosaccharide 
structure and size result in significant changes in the direct, 
microbiota-independent effects.
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